Novo Nordisk: A Long-Term Owner's Perspective

Industry attractiveness remains high, but this is not a risk-free "win-by-default industry." Its upsides are stable chronic-disease demand, fairly sticky products, and high regulatory and manufacturing barriers; its downsides are that once a blockbuster new mechanism or a better formulation appears, share can switch very fast, and payers will use scale and substitutes to push prices down. Lilly's Q1 2026 revenue grew 56% year over year to USD 19.8 billion, with Mounjaro and Zepbound together approaching USD 12.8 billion in the quarter; this shows the obesity/diabetes profit pool is large enough, but also shows that Novo faces a top-tier rival, not a "follower."

On the question of "would I be willing to hold this business if the stock market closed for five years," my answer is: I would hold the business, but not at any price. I rate the business itself 4.5/5 and industry attractiveness 4/5. What truly requires restraint is not doubt about business quality but tolerance on price.

Moat and Management

Novo's moat comes mainly from five things. First, brand and clinical trust. Ozempic and Wegovy are no longer just drug names but among the most recognized GLP-1 brands worldwide. Second, scale and manufacturing. In its Q1 2026 investor materials the company explicitly calls itself the world's largest manufacturer of insulin and GLP-1, with a manufacturing advantage built on years of high-volume biologic API platform experience, continuous production processes, high installed capacity, and in-house development and manufacturing of drug-delivery devices. Third, regulatory and patent barriers. Prescription drugs require clinical, registration, pharmacovigilance, and large-scale compliance systems that ordinary consumer products cannot replicate. Fourth, channel and physician habit. 【Inference】Once a physician prescribing pathway, patient titration pathway, and device-use habit form in chronic-disease treatment, switching is not costless. Fifth, corporate culture and a long-term equity structure. Novo Holdings owns 28.05% of capital and 77.28% of votes, and behind it stands the Novo Nordisk Foundation, which makes the company naturally more long-term-oriented.

But parts of the moat are clearly absent or weak. Novo has no typical network effect; it lacks the self-reinforcing "harder to replace the more users you have" structure of a trading platform or payment system. A data advantage exists, but shows up more as clinical, physician-education, and real-world-evidence accumulation than as internet-style data lock-in. In short, it is a high-barrier pharma moat, not a platform moat.

My judgment on the moat is: still wide, but narrower at the margin than two years ago. Three pieces of evidence support this. First, in Q1 2026 Novo still held about 55% share of once-weekly injectable GLP-1 and kept expanding its country count, showing it remains in a position of strength; second, the 2026 guidance explicitly writes "lower realized prices," "intensifying competition," and "semaglutide losing exclusivity in some international markets," showing earning power being eroded by payers and competitors; third, Lilly brought oral GLP-1 to market in 2026, with formulation differences and price competition reshaping the industry. My score is 4/5, but the trend has shifted from "widening" to "stable, leaning toward contraction."

On management, my view is "broadly credible, but needs to rebuild market trust in the near term." On one hand, Novo's governance clearly leans long-term: the Foundation and Novo Holdings secure long-term capital, the board committee structure is complete, and the company has long followed the Novo Nordisk Way; nor does it merely paper over problems, as Q1 2026 clearly separated reported and adjusted figures, and the remuneration report acknowledged that LTIP 2024 and LTIP 2025 are tracking below target. On the other hand, the 2025 CEO change shows the board was not satisfied with the company's loss of momentum, and the departing CEO's separation package was not small: the remuneration report discloses that Lars Fruergaard Jørgensen's 2025 service-period pay was DKK 22.2 million, plus DKK 36.5 million in notice-period pay, DKK 42.9 million in severance, and DKK 22.0 million in non-compete compensation. This arrangement may not be improper, but it does not look good to minority shareholders.

Management ownership is not extremely high, but these are not entirely "asset-light managers." As of end-2025, CEO Maziar Mike Doustdar held 107,569 shares worth about DKK 35 million; CFO Karsten Munk Knudsen held 238,828 shares worth about DKK 77.7 million, and both met the shareholding requirements. In other words, alignment of interest is "present, but not especially strong." On capital allocation, the company maintained roughly a 50% payout ratio for many years and has long bought back stock; but 2025 buybacks fell to just DKK 1.388 billion, far below the DKK 20.181 billion of 2024, partly because the company entered an intensive capacity-expansion and BD cycle, and partly because buyback execution does not clearly reflect the Buffett-style habit of "buying back aggressively when undervalued." I rate management and capital allocation 3.5/5.

Financial Quality and Owner Earnings

Start with history. From 2019 to 2025, Novo's revenue rose from DKK 122.0 billion to DKK 309.1 billion, a 6-year CAGR of about 16.8%; operating profit rose from DKK 52.5 billion to DKK 127.7 billion, a 6-year CAGR of about 16.0%; net profit rose from DKK 39.0 billion to DKK 102.4 billion, a 6-year CAGR of about 17.5%. From 2021 to 2025, the operating margin held in an extremely high 41%-44% range and the net margin in a 31%-36% range; even as growth slowed markedly in 2025, the net margin was still 33.1%. From the standpoint of "is the business high quality," this is a textbook high-quality pharma asset.

But cash flow cannot be read from the income statement alone. From 2026 Novo changed its free-cash-flow definition, recasting FCF as "operating cash flow minus PP&E purchases," with management stating explicitly this is to "better reflect underlying cash generation." That amounts to the company conceding that, because of acquisitions, intangible investment, and capacity expansion in recent years, the old official FCF no longer works as a simple proxy for "the company's true distributable cash." Reported FCF in 2025 was DKK 28.295 billion, which looks very low; but in the same year PP&E capex reached DKK 60.140 billion and intangible-asset investment reached DKK 29.973 billion, the latter tied mainly to business-development activity, especially the Akero-related transaction. In other words, the low 2025 FCF looks more like a "heavy-investment year" than a sudden loss of cash-generating ability.

On the balance sheet, Novo's financial soundness is very strong. Full-year 2025 net cash was about DKK 95.424 billion, rather than net debt; against 2025 EBITDA of DKK 149.640 billion, net debt/EBITDA is negative, and interest coverage is not a constraint. The company's real risk is not "a debt blowup" but "whether returns can stay very high after heavy capital expansion." That shows up in ROIC: 2021-2024 ROIC was 69.0%, 73.6%, 88.5%, and 63.9%, extremely high; in 2025 it fell to 39.3%, still excellent but clearly down from the peak.

The table below gathers the most important financial outlines of recent years in one place. The 2019-2020 figures come from the 2019/2020 annual reports, and the 2021-2025 figures from the 2025 annual report's "five-year overview"; some ratios are calculated from these raw figures, all on a group-consolidated basis.

On whether "the profit is real cash profit," I split the judgment into two layers. Layer one: net profit itself is very likely real, with no obvious signs of fabrication. The company is a mature multinational pharma with a complete annual-report/20-F framework, and it separately explains the 340B provision reversal, legal matters, and FX effects. Layer two: the cash that truly belongs to shareholders was, over the 2024-2026 window, materially below accounting profit. The reason is not fake profit but capacity expansion, business development, the U.S. gross-to-net system, and working-capital changes squeezing cash release.

On "Owner Earnings," I offer a conservative estimate. 【Fact】The new-definition FCF guidance the company gave for 2026 is DKK 36-46 billion, with PP&E capex of about DKK 55 billion; actual Q1 2026 FCF was DKK 12.8 billion. 【Assumption】Given that a large part of the current DKK 55 billion level of PP&E is clearly expansion rather than maintenance spending, I roughly set long-term maintenance PP&E capex at DKK 25 billion. 【Inference】Then 2026 "conservative owner earnings" can be taken roughly as: midpoint new-definition FCF of DKK 41 billion + (DKK 55 billion total PP&E - DKK 25 billion maintenance PP&E) ≈ DKK 71 billion; applying a further conservative haircut, I take DKK 60 billion as conservative owner earnings. Against the current market cap, that equates to roughly 20-23x conservative owner earnings, an owner earnings yield of about 4.5%-5.0%. This is closer to reality than the static PE and better illustrates that "the price is not clearly cheap."

Valuation and Margin of Safety

As of 2026-05-15, the NVO ADR was about USD 44.74, with a market cap of about USD 197.46 billion. Converted at the ECB reference rate that day, that is roughly DKK 287.5 per ADR. Using 2025 diluted EPS of DKK 23.03, the static PE is about 12.5x; using 2025 equity of DKK 194.047 billion, P/B is about 6.5x; using 2025 net cash and EBITDA, EV/EBITDA is about 7.8x. These figures make many people think at first glance "very cheap"; but if you compute directly off 2025 reported FCF of DKK 28.295 billion, P/FCF runs as high as about 44.8x. That is exactly the point: Novo's biggest valuation difficulty today is not profit but "which cash-flow measure should represent the company's true earning power."

I put more weight on three valuation approaches. Approach one: Owner Earnings discounting. Starting from conservative owner earnings of DKK 60 billion:

• Conservative case: OE grows 3% a year for the next 5 years, then 2% for 5 years, discount rate 10%, terminal growth 2%, accounting for 2025 net cash; this yields about DKK 180-220 per ADR, about USD 28-34 per ADR.

• Base case: OE grows 7% a year for the next 5 years, then 4% for 5 years, discount rate 9%, terminal growth 2.5%; this yields about DKK 260-320 per ADR, about USD 40-50 per ADR.

• Optimistic case: OE grows 10% a year for the next 5 years, then 5% for 5 years, discount rate 8.5%, terminal growth 3%; this yields about DKK 360-430 per ADR, about USD 56-67 per ADR. This is a model, not the truth; but it tells me clearly: the current price sits roughly "in the middle of the fair range," not "below the conservative value range."

Approach two: relative valuation. Compared with Eli Lilly, Novo looks much cheaper. Lilly's current share price is about USD 1,004.92, with a finance-tool PE of about 35.7x; Lilly's 2025 revenue was USD 65.179 billion, net profit USD 20.640 billion, operating cash flow USD 16.813 billion, and capex USD 7.841 billion, with Q1 2026 revenue up another 56% year over year and oral GLP-1 already FDA-approved. By contrast, Novo's static PE, P/S, and EV/EBITDA are all markedly lower. But that does not automatically equal "cheap," because Lilly's growth, formulation progress, and market expectations are all stronger. So relative valuation tells me not "buy Novo immediately" but "the market has shifted from past extreme optimism to a state more skeptical of Novo and more favorable to Lilly."

Approach three: asset/net cash. This company is not suited to liquidation-value valuation, because the real value lies in ongoing operating cash flow, brand, clinical data, manufacturing know-how, and the global registration network, not in tearing down factories and selling equipment. But end-2025 net cash of DKK 95.424 billion does form a downside buffer, equal to about 7%-8% of the current market cap; meanwhile, the biologic API and formulation capacity have real strategic value but are also highly specific, so under a liquidation scenario they should not be valued optimistically at full book. The asset approach tells me two things: downside is not "zero-out risk," but net cash should not be treated as the margin of safety itself either.

On margin of safety, my judgment is clear: it is not clearly cheap now. The three most fragile valuation assumptions are: first, the stability of the U.S. actual net price; second, whether free cash flow can rebound meaningfully once the current capacity-expansion peak passes; third, whether Lilly and oral-GLP-1 competition will rewrite Novo's "high-quality growth" into a "mature pharma, low growth" story. If growth disappoints, margins fall, or the multiple the market assigns keeps contracting, today's buyer's long-term return could still land mediocre, even approaching the 10-year U.S. Treasury yield of 4.47%. On my conservative DKK 60 billion owner earnings estimate, the current owner earnings yield is only about 4.7%, which offers no especially comfortable risk compensation versus Treasuries.

Based on the three approaches above, I offer a price framework:

• Conservative intrinsic-value range: USD 28-34 per ADR

• Fair intrinsic-value range: USD 40-50 per ADR

• Optimistic intrinsic-value range: USD 56-67 per ADR

• Ideal buy-price range: USD 30-38 per ADR

• Acceptable holding-price range: USD 38-50 per ADR

• Clearly overvalued range: above USD 55 per ADR So the current USD 44.74 is closer to "fair but not cheap" than to "a large discount."

Risks, the Bear Case, and Falsification Conditions

The most important risk is not share-price volatility but permanent loss of capital. For Novo, the most critical permanent-loss paths number six. First, competition risk. Lilly's Mounjaro/Zepbound are still growing fast, and oral GLP-1 Foundayo already has FDA approval. Second, price and channel risk. Novo's 2026 guidance explicitly says realized prices are falling, and that the U.S. gross-to-net, Most Favoured Nations policy, and 340B matters will keep affecting performance. Third, exclusivity risk. The company itself has noted that semaglutide is losing exclusivity in some international markets. Fourth, return-on-capital decline risk. If the large-scale capacity expansion and business-development investment of the past three years cannot translate into future cash flow, it will pull historically high ROIC toward the average of an ordinary large pharma. Fifth, business-model disruption. The FDA has announced the semaglutide injection shortage is resolved and routine compounding should be restricted, but cheaper compounded oral/online channel tactics could keep disrupting price perception. Sixth, management and governance risk. The 2025 CEO change shows the company's operations are not flawless.

The strongest counterargument is in fact quite powerful: "Novo is one of the biggest winners of the last GLP-1 narrative, but its best days may be behind it; it is still a good company, yet not necessarily the best odds for the next decade." What a bear is most likely to see is three things. First, Novo's advantage still centers mainly on the semaglutide family, while Lilly has built a stronger offensive across multi-target, oral, and U.S. commercial execution. Second, Novo's Q1 2026 reported figures look good, but adjusted sales and operating profit on a CER basis were -4% and -6% respectively, which is not an easy "still charging ahead" report. Third, the seemingly modest static PE masks the reality that cash recovery and reinvestment burden remain heavy.

What facts would make me admit I was wrong and reassess? If I see the following, I would lean toward conceding the investment does not hold:

• Novo cannot meaningfully repair FCF/owner earnings in 2026-2027 while total capex also fails to fall significantly;

• Lilly keeps widening its lead in the core obesity and diabetes markets, and Novo's once-weekly injectable GLP-1 share clearly breaks below the roughly 55% level and keeps deteriorating;

• Oral Wegovy commercialization has volume but must be sold at lower prices over the long term, so new users do not bring reasonable profit;

• The company keeps piling on large pipeline/BD investment, but per-share intrinsic value stops growing. These would all mean the problem is not just "cyclical fluctuation" but a structural change of "a narrowing moat and falling capital-allocation returns."

Checklist and Final Conclusion

First, a checklist-style judgment. Here I try to use "pass / fail / uncertain" rather than vague wording.

The conclusion behind this checklist is simple: business quality passes, financial soundness passes, valuation discipline does not yet pass. It is not a company that "should be avoided"; on the contrary, it is a high-quality asset worth close tracking; but high quality itself cannot substitute for a margin of safety.

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Novo Nordisk remains one of the world's finest chronic-disease pharma companies, but with Lilly attacking faster, the U.S. pricing system under pressure, and the company still in a high-investment phase, the current price looks more like a "fair price" than a "low-risk good price."

【Core Bull Case】

• Long-term demand is clear: the global obesity and diabetes burden is still rising.

• Commercial quality is excellent: high revenue and net-profit growth from 2019 to 2025, with extremely high margins and ROIC sustained over the long term.

• The moat is real: brand, clinical evidence, device and manufacturing capability, global registration, and the Foundation control structure are all hard to replicate.

• The balance sheet is strong: 2025 net cash of about DKK 95.4 billion.

• The static valuation is much cheaper than Lilly's, and the market has shifted from extreme optimism to greater restraint.

【Core Bear Case】

• Adjusted Q1 2026 results were not strong, and the reported figures are distorted by a one-off non-cash 340B item.

• Competition is intensifying, Lilly's obesity business is growing faster, and an oral formulation is already approved.

• The pricing system is under pressure, and Novo itself has written lower realised prices, competition, and exclusivity loss into its 2026 guidance.

• Cash-flow release is still suppressed by high capex and business-development investment.

• The current owner earnings yield does not offer clear excess compensation versus the 10-year U.S. Treasury yield.

【Key Assumptions】

• The company can still maintain leading share in the core obesity/diabetes markets, rather than steadily ceding pricing power to Lilly.

• After the 2026-2028 capacity-expansion peak passes, FCF/Owner Earnings will rebound.

• The change in semaglutide exclusivity and U.S. channel pressure will not permanently push the long-term net margin down to ordinary large-pharma levels.

• Oral and next-generation obesity pipelines can take the baton, rather than overdrawing on existing products alone.

• Over the next three years management pulls capital allocation back toward "per-share intrinsic-value growth."

【Fair Buy Price】 USD 30-38 per ADR is more ideal; USD 38-50 per ADR is acceptable but without a thick margin of safety; above USD 55 I would consider clearly expensive. The basis is the three-scenario Owner Earnings DCF, the net-cash buffer, and relative valuation cross-checking one another.

【Target Holding Period】 If buying, hold on a scale of at least 5-10 years, preferably 10-plus years; but the precondition is continuously tracking the pricing system, share, and cash flow, not "buy and forget."

【Expected Annualized Return】 This is a model projection, not a promise.

• Conservative case: about 1%-4% a year

• Neutral case: about 7%-10% a year

• Optimistic case: about 12%-15% a year The range is wide because this company's return now depends more on the pricing system and cash-flow recovery than on volume growth alone.

【Maximum Loss Risk】 If the competitive landscape in obesity worsens, U.S. realized prices keep falling, and heavy-capital expansion returns disappoint, then on my conservative valuation range the current price carries about 24%-37% of downside over the medium-to-long term; if it further evolves into a "mature pharma, low growth plus low multiple" combination, in an extreme case downside could reach above 40%. This is an inference based on a conservative owner earnings model, not a forecast of the short-term share price.

【Tracking Metrics】 Going forward I will focus on these 8 items:

• Adjusted sales growth and adjusted operating-profit growth

• U.S. gross-to-net, net price, and policy effects such as 340B/MFN

• Market-share shifts between Wegovy/Ozempic and Lilly's competing products

• Oral Wegovy's volume, price, and gross-margin structure

• Whether PP&E capex rolls off from its high level

• Whether FCF and my defined Owner Earnings keep recovering

• The actual impact of semaglutide's changing exclusivity in international markets

• Whether the next-generation pipeline and BD investment can deliver high returns

【Signals Triggering Reassessment】

• For more than two consecutive quarters, the adjusted operating trend runs weaker than management's own stated recovery path

• Share keeps being taken by Lilly with no product counterattack

• Capex stays high but cash flow does not recover

• A major legal/rebate/channel-accounting item again significantly distorts the statements

• Valuation instead climbs back above the optimistic range

【Final Recommendation】 The calm conclusion is this: this is an excellent company worth holding long-term at "the very front of the watch list," but not a cheap price that already offers a sufficient margin of safety today. If you already own it, I lean toward "patient holding, close tracking"; if you are preparing to open a new position, I would choose to keep waiting until the market again brings the price to a level where "even the conservative case is acceptable." For long-term value investors, the hardest thing is not finding a good company but keeping price discipline in front of a good company.

Open Questions and Limitations

To avoid fabrication or miscalculation, I am deliberately conservative on three points:

• The full 2025 operating cash flow and working-capital breakdown could not be fully laid out in the currently accessible excerpts, so Owner Earnings uses a conservative normalized estimate rather than a falsely precise figure.

• In peer comparison I prioritize the data of Novo and Lilly, the two most critical players; for other peers, if static measures such as P/B or ROIC lack first-hand or reliable excerpt support, I choose to omit them.

• The valuation range is a conservative framework built around long-term cash-generating ability, not a short-term target price.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.